Prathyusha Duraibabu is SVP, CHIEF FINANCIAL OFFICER of SANGAMO THERAPEUTICS, INC. Currently has a direct ownership of 827,370 shares of SGMO, which is worth approximately $1.41 Million. The most recent transaction as insider was on Aug 25, 2024, when has been sold 1,371 shares (Common Stock) at a price of $0.86 per share, resulting in proceeds of $1,179. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 827K
0.38% 3M change
525.21% 12M change
Total Value Held $1.41 Million

Prathyusha Duraibabu Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 25 2024
SELL
Payment of exercise price or tax liability
$1,179 $0.86 p/Share
1,371 Reduced 0.17%
827,370 Common Stock
Aug 24 2024
SELL
Payment of exercise price or tax liability
$1,536 $0.86 p/Share
1,787 Reduced 0.22%
828,741 Common Stock
Jun 11 2024
SELL
Payment of exercise price or tax liability
$544 $0.61 p/Share
892 Reduced 0.11%
830,528 Common Stock
May 25 2024
SELL
Payment of exercise price or tax liability
$822 $0.6 p/Share
1,371 Reduced 0.16%
831,420 Common Stock
May 24 2024
SELL
Payment of exercise price or tax liability
$1,072 $0.6 p/Share
1,787 Reduced 0.21%
832,791 Common Stock
Feb 25 2024
SELL
Payment of exercise price or tax liability
$3,901 $1.13 p/Share
3,453 Reduced 0.41%
834,578 Common Stock
Feb 24 2024
SELL
Payment of exercise price or tax liability
$6,185 $1.13 p/Share
5,474 Reduced 0.65%
838,031 Common Stock
Jan 22 2024
BUY
Grant, award, or other acquisition
-
712,500 Added 45.79%
843,505 Common Stock
Nov 25 2023
SELL
Payment of exercise price or tax liability
$505 $0.38 p/Share
1,329 Reduced 1.0%
131,005 Common Stock
Aug 25 2023
SELL
Payment of exercise price or tax liability
$1,023 $0.77 p/Share
1,329 Reduced 0.99%
132,334 Common Stock
Jun 11 2023
SELL
Payment of exercise price or tax liability
$1,028 $1.19 p/Share
864 Reduced 0.64%
133,663 Common Stock
May 25 2023
SELL
Payment of exercise price or tax liability
$1,766 $1.33 p/Share
1,328 Reduced 1.0%
132,052 Common Stock
Mar 25 2023
SELL
Payment of exercise price or tax liability
$572 $1.66 p/Share
345 Reduced 0.26%
133,380 Common Stock
Feb 25 2023
SELL
Payment of exercise price or tax liability
$18,699 $2.66 p/Share
7,030 Reduced 4.99%
133,725 Common Stock
Feb 24 2023
BUY
Grant, award, or other acquisition
-
53,438 Added 27.52%
140,755 Common Stock
Jun 11 2022
SELL
Payment of exercise price or tax liability
$3,166 $3.76 p/Share
842 Reduced 0.96%
86,617 Common Stock
Apr 25 2022
SELL
Payment of exercise price or tax liability
$3,197 $4.83 p/Share
662 Reduced 0.76%
86,772 Common Stock
Mar 25 2022
SELL
Payment of exercise price or tax liability
$1,984 $5.75 p/Share
345 Reduced 0.39%
87,434 Common Stock
Feb 25 2022
SELL
Payment of exercise price or tax liability
$20,497 $5.9 p/Share
3,474 Reduced 6.91%
46,779 Common Stock
Feb 25 2022
BUY
Grant, award, or other acquisition
-
41,000 Added 31.84%
87,779 Common Stock
Jun 11 2021
BUY
Grant, award, or other acquisition
-
7,500 Added 13.08%
49,827 Common Stock
Apr 25 2021
SELL
Payment of exercise price or tax liability
$7,752 $11.71 p/Share
662 Reduced 1.62%
40,128 Common Stock
Mar 25 2021
SELL
Payment of exercise price or tax liability
$4,233 $12.27 p/Share
345 Reduced 0.84%
40,790 Common Stock
Feb 25 2021
SELL
Payment of exercise price or tax liability
$20,847 $11.19 p/Share
1,863 Reduced 6.37%
27,385 Common Stock
Feb 25 2021
BUY
Grant, award, or other acquisition
-
13,750 Added 25.05%
41,135 Common Stock

Also insider at

ORGO
Organogenesis Holdings Inc. Healthcare
PD

Prathyusha Duraibabu

SVP, CHIEF FINANCIAL OFFICER
Canton, MA

Track Institutional and Insider Activities on SGMO

Follow SANGAMO THERAPEUTICS, INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SGMO shares.

Notify only if

Insider Trading

Get notified when an Sangamo Therapeutics, Inc insider buys or sells SGMO shares.

Notify only if

News

Receive news related to SANGAMO THERAPEUTICS, INC

Track Activities on SGMO